We are happy to announce that Redoxis AB is a partner in a research project called “Targeting he melanocortin system as a novel strategy to reduce inflammation during vascular disease” led by Senior Lecturer Liza Ljungberg, School of Medical Sciences at Örebro University. The project was funded by a research grant of SEK 4 million from The Knowledge Foundation, funding research and competence development at Swedish universities. Redoxis will contribute to the project, that is planned to start 1st of July 2021, with expertise in preclinical drug development and efficacy assessment in both disease models and functional assays. 

“Participating in this project is in line with Redoxis aim to continuously expand competence area, implement new clinically relevant models and stay closely connected with academic research in our quest to be the best contract research organization in preclinical inflammatory research” says Malin Hultqvist Hopkins, CEO of Redoxis AB

The project is a collaboration between Örebro University, SynAct Pharma AB and Redoxis AB.